This ExpertREACT article was originally published on 30 October 2008 following the 48th Annual ICAAC/IDSA in Washington DC. Conference presentations and clinical data described reflect the state of knowledge at that date.
PCV-7 impact and PCV-13 preparation
A series of CDC-presented posters documented the public health impact of Prevnar (PCV-7) since its introduction to the routine infant schedule globally. Estimations presented at the conference suggested that PCV-7 had prevented approximately 210,000 cases of invasive pneumococcal disease (IPD) and saved around 14,000 lives in the US, of which approximately 50% were in adults through herd immunity effects. The vaccine had achieved a ~92% reduction in vaccine-type IPD in the elderly through these indirect effects, though an increase in non-vaccine serotypes - particularly 19A - was observed. Wyeth presented Phase III data for PCV-13, its 13-valent follow-on vaccine, showing non-inferior immunogenicity to PCV-7 for the 7 shared serotypes and functional antibodies for all 13 serotypes. Wyeth expected to complete its US regulatory filing for PCV-13 paediatric use in Q1 2009.
In rotavirus vaccines, Merck & Co and GSK Biologicals presented updated data from their respective RotaTeq and Rotarix programmes, with both companies providing evidence on the real-world impact of rotavirus vaccination across different geographies. The competitive dynamics between the two products - different dosing schedules, serotype coverage and safety profiles - were the subject of several comparative poster analyses. In meningococcal vaccines, Novartis provided background and updated data on its MenB (4CMenB/Bexsero) candidate and MenACWY-CRM (Menveo) programme, with both products on track for EU filing timelines.
Sanofi Fluzone High Dose: data for the elderly
Sanofi released clinical data for Fluzone High Dose (HD), its influenza vaccine containing 60μg of influenza antigens per dose - four times the standard 15μg - for adults 65 years and older. The data demonstrated meaningfully improved immunogenicity compared to standard-dose Fluzone in this age group, addressing the well-documented problem of reduced influenza vaccine immunogenicity in elderly populations due to immunosenescence. VacZine Analytics viewed Fluzone HD as an important differentiating product for Sanofi in the highly competitive US influenza market, and one that addressed a genuine clinical need in a high-priority population.